Flash Buy: Phase 3 Results Have Huge Potential
It’s estimated that 12% of the U.S. population has NASH, with the number rising to 70% in diabetic and obese people over 50. It’s a big market for any drug developer that can bring a solution through the FDA. And today’s play might be that answer…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.